| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.05B | 1.05B | 1.17B | 1.64B | 1.16B | 877.16M |
| Gross Profit | 30.59M | 236.71M | 41.90M | 447.48M | 270.43M | 190.88M |
| EBITDA | -31.45M | 163.93M | -28.75M | 390.21M | 211.36M | 157.09M |
| Net Income | -87.22M | 66.15M | -85.33M | 199.23M | 103.62M | 68.90M |
Balance Sheet | ||||||
| Total Assets | 1.51B | 1.67B | 1.54B | 1.89B | 1.70B | 1.43B |
| Cash, Cash Equivalents and Short-Term Investments | 64.53M | 128.47M | 84.10M | 43.50M | 139.36M | 175.38M |
| Total Debt | 588.34M | 601.33M | 601.97M | 649.27M | 624.50M | 498.94M |
| Total Liabilities | 731.39M | 768.39M | 789.49M | 938.99M | 837.68M | 674.66M |
| Stockholders Equity | 768.91M | 893.68M | 745.24M | 945.20M | 841.98M | 746.25M |
Cash Flow | ||||||
| Free Cash Flow | 160.15M | 66.83M | 84.75M | -82.78M | -16.41M | -49.42M |
| Operating Cash Flow | 188.21M | 116.95M | 96.52M | -32.19M | 61.11M | 11.64M |
| Investing Cash Flow | -21.76M | -46.59M | -8.13M | -51.60M | -137.17M | -57.65M |
| Financing Cash Flow | -146.51M | -39.93M | -20.55M | -5.01M | 99.46M | 44.04M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$287.92M | 18.05 | 5.90% | ― | 14.31% | -8.40% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
51 Neutral | HK$542.98M | 17.95 | 3.41% | 1.90% | -10.60% | ― | |
51 Neutral | HK$75.32M | -0.31 | -30.07% | ― | -3.16% | 33.72% | |
48 Neutral | HK$42.84M | ― | -7.84% | ― | -15.08% | 12.98% | |
45 Neutral | HK$160.39M | -0.98 | -42.06% | 9.69% | -41.81% | -645.06% |
Green Fresh Biotechnology Company Limited reported a decline in financial performance for the first half of 2025, with revenue decreasing by 10.7% to RMB410.0 million compared to the same period in 2024. The company experienced a net loss of RMB12.3 million, a significant drop from a net profit of RMB22.6 million in the previous year, leading to a decision not to distribute interim dividends. This downturn reflects challenges in maintaining profit margins and managing costs, impacting its market positioning and shareholder returns.
Green Fresh Biotechnology Company Limited has announced that its board of directors will hold a meeting on August 28, 2025, to approve the interim results for the first half of the year and consider the recommendation of an interim dividend. This announcement indicates the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting investor confidence and market positioning.
Green Fresh Biotechnology Company Limited has issued a profit warning for the first half of 2025, anticipating a net loss of approximately RMB11.0 million to RMB13.5 million, compared to a net profit of RMB23.08 million in the same period of 2024. The decline in performance is attributed to reduced selling prices and sales quantities of major products, alongside increased research and development expenses. The company is finalizing its interim results, which are expected to be published by the end of August 2025.